Biologics & Pharmaceutical Patent LitigationPrescribed Solutions
In order to succeed in the ever-competitive pharmaceutical marketplace, generic pharmaceutical and drug development companies require legal counsel with a deep understanding of the Hatch-Waxman Act, BPCIA, and related statutes; extensive patent law experience; and unique insight into a company’s technology. At Kilpatrick Townsend, our specially-assembled litigation team brings a fresh approach when handling biologics and pharmaceutical patent litigation, having successfully represented some of the world’s largest generic pharmaceutical companies. Our team includes former scientists, engineers, patent examiners, and federal law clerks — many with vast pharmaceutical industry experience as regulators, developers, trial designers, marketing managers, and in-house attorneys — giving us keen business insight to provide well-rounded client results. Our services span the gamut of pharmaceutical-related patent litigation — including pre-litigation due diligence, analysis, patent validity and infringement opinion preparation, Paragraph IV letters, and federal pharmaceutical patent litigation. Many of our litigators bring a long and successful history litigating patent and Hatch-Waxman matters in all jurisdictions, including numerous cases in Delaware and New Jersey — the predominant venues for Hatch-Waxman litigation and the corporate headquarters for many pharmaceutical companies.
Mitchell G. Stockwell
D. Clay Holloway